The effect of cladribine on T1 'black hole' changes in progressive MS

M. Filippi, M. Rovaris, G. P A Rice, M. P. Sormani, G. Iannucci, L. Giacomotti, G. Comi

Research output: Contribution to journalArticlepeer-review


We compared the changes of the volumes of T1-hypointense lesions seen on the magnetic resonance imaging scans of the brain from 159 progressive multiple sclerosis (MS) patients who were enrolled in a double-blind, placebo-controlled trial assessing the efficacy of two doses of cladribine. Although in patients treated with cladribine there was a tendency to have a lower increase of T1-hypointense lesion volumes than those treated with placebo, no statistically significant effect of cladribine on T1-hypointense lesion accumulation was found over the one-year double-blind phase. Furthermore, no significant treatment effect was also detected in a subset of 22 patients who received placebo during the double-blind phase of the study and cladribine during the subsequent one-year open-label phase. We conclude that cladribine does not have a major impact on the mechanisms leading to severe tissue destruction in progressive MS. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)42-44
Number of pages3
JournalJournal of the Neurological Sciences
Issue number1
Publication statusPublished - May 1 2000


  • Cladribine
  • MRI
  • MS
  • T-hypointense lesions

ASJC Scopus subject areas

  • Ageing
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)


Dive into the research topics of 'The effect of cladribine on T1 'black hole' changes in progressive MS'. Together they form a unique fingerprint.

Cite this